Targovax grants Zelluna Immunotherapy an FTO license to intellectual property relating to mutant RAS T cell receptor technology
· Targovax grants Zelluna an FTO license to Targovax patents and know-how to further enable development of Zelluna’s mutant RAS T-cell receptor therapies · Targovax and Zelluna intend to collaborate on additional discovery and development of novel mutant RAS T cell receptors Oslo, Norway, 14 March 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that it has granted a freedom-to-operate (FTO) license to Zelluna Immunotherapy for the development of mutant RAS T cell receptor (